|
Volumn 20, Issue 11, 2001, Pages 800-803
|
Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects
|
Author keywords
[No Author keywords available]
|
Indexed keywords
APL400 003;
AUTOANTIBODY;
CD4 ANTIGEN;
CD8 ANTIGEN;
DNA VACCINE;
GLYCOPROTEIN GP 160;
HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;
HUMAN IMMUNODEFICIENCY VIRUS VACCINE;
ADULT;
ARTICLE;
BLOOD LEVEL;
CASE REPORT;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE COURSE;
DOSE RESPONSE;
DRUG EFFECT;
DRUG SAFETY;
DRUG SCREENING;
FEMALE;
FOLLOW UP;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LYMPHOCYTE COUNT;
MALE;
PHASE 1 CLINICAL TRIAL;
PLASMID;
PRIORITY JOURNAL;
UNITED STATES;
VIRUS CONCENTRATION;
ADULT;
AIDS VACCINES;
FEMALE;
FOLLOW-UP STUDIES;
HIV ENVELOPE PROTEIN GP160;
HIV INFECTIONS;
HIV SEROPOSITIVITY;
HIV-1;
HUMANS;
IMMUNIZATION SCHEDULE;
MALE;
PATIENT SELECTION;
SEVERITY OF ILLNESS INDEX;
TREATMENT OUTCOME;
VACCINATION;
|
EID: 0035659523
PISSN: 09349723
EISSN: None
Source Type: Journal
DOI: 10.1007/s100960100578 Document Type: Article |
Times cited : (24)
|
References (14)
|